Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q3 2024 Earnings Presentation
13 slides from Pacira Biosciences's earnings presentation, Nov 6, 2024
Slide 1: 3Q24 Earnings
BIOSCIENCES, INC. BETTER /8 POSSIBLE. 3Q24 Earnings
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, wi
Slide 3: Important progress in three key areas
Important progress in three key areas Refreshed mission to deliver Defined a growth-oriented, Foundation in place for innovative, non-opioid pain long-term plan and therapeutic modernized, best-practice therapies to transform area strategy focused on Commercial, Market the lives of patients musculos
Slide 4: Expanding EXPAREL utilization ahead of NOPAIN
Expanding EXPAREL utilization ahead of NOPAIN • Streamlines reimbursement and coding process • 2nd GPO partnership following Premier earlier this year • More likely to be recognized and covered by • Third and final GPO partnership on track for end of commercial payers 2025/early 2026 – Will cover an
Slide 5: ZILRETTA and iovera performing according to plan with solid 3Q sales
ZILRETTA and ioveraº performing according to plan with solid 3Q sales ZILRETTA ioveraº Phase 3 shoulder OA study progressing; topline Qualified for separate outpatient reimbursement results expected in 2026 as part of NOPAIN with newly created product- specific code (C-9809) beginning January 2025 •
Slide 6: PCRX-201: Redefining innovation in gene therapy to bring its benefit to the population at large
PCRX-201: Redefining innovation in gene therapy to bring its benefit to the population at large PCRX-201’s innovative design, manufacturing process, and local administration solve many of the challenges that have made gene therapy inaccessible for common diseases PCRX-201 is injected locally into PC
Slide 7: PCRX-201: 75% of patients achieved a 50+% improvement in pain and stiffness
PCRX-201: 75% of patients achieved a 50+% improvement in pain and stiffness Sustained efficacy and safety for moderate-to-severe OAK after a single intraarticular injection Data presented at OARSI 2024 and ASGCT 2024* WOMAC Pain WOMAC Stiffness • 72 adult patients aged 30 to 80 with moderate to seve
Slide 8: PCRX-201 educational webinars
PCRX-201 educational webinars An Introduction to PCRX-201: ACR Convergence 2024: Developing a Transformative Innovation PCRX-201 2-Year Data In Treatment of Knee Osteoarthritis Stanley Cohen, MD Derek Jackson Click Here Coming Soon PACIRA Better is possible. 8
Slide 9: Defending our intellectual property and the proven safety and integrity of EXPAREL
Defending our intellectual property and the proven safety and integrity of EXPAREL • ‘495 only the patent litigation case • Comprehensive legal strategy; appeal process is underway • Team continues to innovate with additional patents forthcoming • Awaiting trial date for 2nd lawsuit involving ‘574 p
Slide 10: Strong financial footing with a business that is generating significant cash flow
Strong financial footing with a business that is generating significant cash flow • 3Q24 total revenue of 2024 Financial Guidance Reiterated as of 3Q24 – EXPAREL net product sales of $132M Total Revenue $680-705M – ZILRETTA net product sales of $28M Non-GAAP Gross Margins 74-76% – ioveraº net produc
Slide 11: Website, Investor toolkit, Social
Website Investor-toolkit Social: X Social: LinkedIn
Slide 12: Appendix
APPENDIX PACIRA Better is possible. 12
Slide 13: Non-GAAP disclosure
Non-GAAP disclosure PACIRA Better is possible. 13